F. Hoffmann-La Roche Ltd: FDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma

First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma Application is based on pivotal data from the phase III POLARIX study

Related Keywords

Lugano ,Ticino ,Switzerland ,Japan ,United States ,America ,Gazyvaro Gazyva ,Mabthera Rituxan ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Venclexta Venclyxto ,Birgit Masjost ,Sileia Urech ,Loren Kalm ,Karsten Kleine ,Nathalie Altermatt ,Genentech ,Lymphoma Study Association ,Roche Group ,Roche Group Media Relations ,Lymphoma Academic Research Organisation ,Lugano Response Criteria ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Hoffmann ,Oche ,Oaccepts ,Supplemental ,Iologics ,License ,Application ,Polivy ,Combination ,People ,Reviously ,Untreated ,Diffuse ,Barge ,Fell ,Lymphoma ,